Lamivudine Teva Pharma B.V. (Lamivudine)

Lamivudine is a nucleoside analog that, after entering cells, is converted to its active triphosphate form. This active metabolite competitively inhibits the reverse transcriptase enzyme of HIV and the DNA polymerase of hepatitis B virus, leading to premature termination of viral DNA synthesis and reduced viral replication.

The specific dose of Lamivudine is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, renal function, and other clinical factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety data for Lamivudine in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should only be used if the potential benefits justify the potential risks to the fetus. Breastfeeding decisions should be made in consultation with a healthcare provider, considering possible drug exposure to the infant.

To order Lamivudine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any required import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with other NRTIs, it has a favorable safety profile and is effective against both HIV and hepatitis B, making it a versatile component of combination regimens.

Lamivudine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lamivudine is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include lactic acidosis, severe hepatotoxicity, pancreatitis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these conditions, and therapy should be discontinued immediately if any serious adverse events occur.

Lamivudine should be avoided in individuals with known hypersensitivity to the drug or any of its components. Patients with severe hepatic impairment or those who have experienced serious adverse reactions to other NRTIs should discuss alternative therapies with their healthcare provider.